These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21804916)

  • 1. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.
    Ehlén Å; Nodin B; Rexhepaj E; Brändstedt J; Uhlén M; Alvarado-Kristensson M; Pontén F; Brennan DJ; Jirström K
    Transl Oncol; 2011 Aug; 4(4):212-21. PubMed ID: 21804916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
    Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
    Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRR11 unveiled as a top candidate biomarker within the RBM3-regulated transcriptome in pancreatic cancer.
    Olsson Hau S; Wahlin S; Cervin S; Falk V; Nodin B; Elebro J; Eberhard J; Moran B; Gallagher WM; Karnevi E; Jirström K
    J Pathol Clin Res; 2022 Jan; 8(1):65-77. PubMed ID: 34379360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.
    Jonsson L; Bergman J; Nodin B; Manjer J; Pontén F; Uhlén M; Jirström K
    J Transl Med; 2011 Jul; 9():114. PubMed ID: 21777469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.
    Ye F; Jin P; Cai X; Cai P; Cai H
    Med Sci Monit; 2017 Dec; 23():6033-6041. PubMed ID: 29263314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer.
    Salomonsson A; Micke P; Mattsson JSM; La Fleur L; Isaksson J; Jönsson M; Nodin B; Botling J; Uhlén M; Jirström K; Staaf J; Planck M; Brunnström H
    Cancer Med; 2020 Aug; 9(15):5609-5619. PubMed ID: 32491279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.
    Boman K; Andersson G; Wennersten C; Nodin B; Ahlgren G; Jirström K
    Biomark Res; 2017; 5():10. PubMed ID: 28293425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer.
    Kang SH; Cho J; Jeong H; Kwon SY
    J Breast Cancer; 2018 Sep; 21(3):288-296. PubMed ID: 30275857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer.
    Nodin B; Fridberg M; Uhlén M; Jirström K
    J Ovarian Res; 2012 Jan; 5(1):6. PubMed ID: 22284433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification.
    Karnevi E; Dror LB; Mardinoglu A; Elebro J; Heby M; Olofsson SE; Nodin B; Eberhard J; Gallagher W; Uhlén M; Jirström K
    Oncotarget; 2018 Jan; 9(5):6188-6200. PubMed ID: 29464064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe.
    Sureban SM; Ramalingam S; Natarajan G; May R; Subramaniam D; Bishnupuri KS; Morrison AR; Dieckgraefe BK; Brackett DJ; Postier RG; Houchen CW; Anant S
    Oncogene; 2008 Jul; 27(33):4544-56. PubMed ID: 18427544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
    Jonsson L; Gaber A; Ulmert D; Uhlén M; Bjartell A; Jirström K
    Diagn Pathol; 2011 Sep; 6():91. PubMed ID: 21955582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.
    Siesing C; Sorbye H; Dragomir A; Pfeiffer P; Qvortrup C; Pontén F; Jirström K; Glimelius B; Eberhard J
    PLoS One; 2017; 12(8):e0182512. PubMed ID: 28800641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.
    Hjelm B; Brennan DJ; Zendehrokh N; Eberhard J; Nodin B; Gaber A; Pontén F; Johannesson H; Smaragdi K; Frantz C; Hober S; Johnson LB; Påhlman S; Jirström K; Uhlen M
    Proteomics Clin Appl; 2011 Dec; 5(11-12):624-35. PubMed ID: 21956899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic and clinicopathological significance of RBM3 in the survival of patients with tumor: A Prisma-compliant meta-analysis.
    Gao G; Shi X; Long Y; Yao Z; Shen J; Shen L
    Medicine (Baltimore); 2020 May; 99(19):e20002. PubMed ID: 32384455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.
    Olofsson SE; Nodin B; Gaber A; Eberhard J; Uhlén M; Jirström K; Jerkeman M
    PLoS One; 2015; 10(3):e0121300. PubMed ID: 25811459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.